A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Rivogenlecleucel (Primary) ; Rimiducid
- Indications Graft-versus-host disease; Haematological malignancies; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Bellicum Pharmaceuticals
- 30 Jan 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Dec 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019.
- 01 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 1 Nov 2018.